SIC
UTHR icon

SJS Investment Consulting’s United Therapeutics UTHR Stock Holding History

SJS Investment Consulting’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$29.3K Buy
54
+3
+6% +$1.69K ﹤0.01% 651
2026
Q1 		$30.2K Sell
51
-23
-31% -$11.5K ﹤0.01% 548
2025
Q4 		$36.1K Buy
74
+69
+1,380% +$32.1K ﹤0.01% 466
2025
Q3 		$2.1K Sell
5
-1
-17% -$336 ﹤0.01% 814
2025
Q2 		$1.73K Sell
6
-3
-33% -$897 ﹤0.01% 624
2025
Q1 		$2.77K Hold
9
– – ﹤0.01% 603
2024
Q4 		$3.18K Sell
9
-2
-18% -$735 ﹤0.01% 547
2024
Q3 		$3.94K Hold
11
– – ﹤0.01% 543
2024
Q2 		$3.5K Hold
11
– – ﹤0.01% 520
2024
Q1 		$2.53K Sell
11
-2
-15% -$451 ﹤0.01% 650
2023
Q4 		$2.86K Hold
13
– – ﹤0.01% 531
2023
Q3 		$2.94K Buy
13
+2
+18% +$461 ﹤0.01% 487
2023
Q2 		$2.43K Buy
11
+6
+120% +$1.33K ﹤0.01% 531
2023
Q1 		$1.12K Sell
5
-11
-69% -$2.71K ﹤0.01% 847
2022
Q4 		$4.45K Buy
16
+7
+78% +$1.77K ﹤0.01% 380
2022
Q3 		$2K Buy
+9
New +$2.01K ﹤0.01% 550
2022
Q1 		$0 Buy
+2
New +$381 ﹤0.01% 1352

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

SJS Investment Consulting's UTHR Position: Q2 2026 in Review

SJS Investment Consulting increased its United Therapeutics (UTHR) stake by 5.9% in Q2 2026, buying an estimated $1.69K and bringing the position to 54 shares worth $29.3K. The position accounts for ﹤0.01% of the portfolio, ranked #651.

SJS Investment Consulting first reported a position in UTHR in Q1 2022 and has held it in 17 quarters since. The position peaked at $36.1K in Q4 2025. 883 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • SJS Investment Consulting held 54 shares of United Therapeutics worth $29.3K as of Q2 2026.
  • SJS Investment Consulting bought 3 United Therapeutics shares in Q2 2026, an estimated $1.69K.
  • United Therapeutics made up ﹤0.01% of SJS Investment Consulting's portfolio in Q2 2026, its #651 holding.
  • SJS Investment Consulting first reported a position in United Therapeutics in Q1 2022 and has held it in 17 quarters since.
  • SJS Investment Consulting's United Therapeutics position peaked at $36.1K in Q4 2025.
  • 883 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on SJS Investment Consulting's 13F filing for Q2 2026, filed 22 Jul 2026.